Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

Next Previous
Trial Profile

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Eczema
  • Focus Registrational; Therapeutic Use
  • Acronyms DELTA 2
  • Sponsors LEO Pharma

Most Recent Events

  • 08 Mar 2025 According to a LEO Pharma media release, separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, Orlando, Florida. 7-11 March. E-poster ; evaluated systemic exposure analysis in patients following high use of delgocitinib cream to treat moderate to severe CHE.
  • 03 Dec 2024 According to a LEO Pharma media release, company announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for delgocitinib cream for the treatment of adult patients with moderate to severe Chronic Hand Eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.
  • 23 Oct 2024 According to a Leo Pharma media release, data from this study will be presented at the 2024 Fall Clinical Dermatology Conference taking place from Oct. 24-27 in Las Vegas, Nevada.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top